DNA-methyltransferases (DNMTs) are a class of epigenetic enzymes that catalyze the transfer of a methyl moiety from the methyl donor S-adenosyl-L-methionine onto the C5 position of cytosine in DNA. This process is dysregulated in cancers and leads to the hypermethylation and silencing of tumor suppressor genes. The development of potent and selective inhibitors of DNMTs is of utmost importance for the discovery of new therapies for the treatment of cancer. We report herein the synthesis and DNMT inhibitory activity of 29 analogues derived from NSC 319745. The effect of selected compounds on the methylation level in the MDA-MB-231 human breast cancer cell line was evaluated using a luminometric methylation assay. Molecular docking studies have been conducted to propose a binding mode for this series.
Introduction
Epigenetics is dened as the changes that occur on chromosomes without alteration of the DNA sequence and that lead to a stable phenotype.
1 Epigenetic information is regulated by chromatin modications, which involve histones and DNA.
2
DNA methylation is a stable epigenetic modication leading to the installation of a methyl group at the C5 position of cytosine.
3
This reaction is catalyzed by DNA methyltransferase (DNMT) enzymes, which use S-adenosyl-L-methionine (SAM) as methyl donor. The products of the reaction are 5-methylcytosine in DNA and S-adenosyl-L-homocysteine (SAH). 4 Five DNMTs have been identied: DNMT1, DNMT2, DNMT3A, DNMT3B, and DNMT3L. However, only DNMT1 and DNMT3A/B are catalytically active on DNA. In fact, DNMT2 has a very weak DNA methylation activity and rather performs the methylation of tRNA Asp . 5 DNMT3L is catalytically inactive since it lacks the necessary catalytic domain. However, DNMT3L has been found to associate with DNMT3A/B to modulate its activity. DNMT3A/ B are involved in de novo methylation of DNA, initiating methylation on a strand of DNA that is complementary to either the unmethylated or methylated DNA template. Thus, DNMT3A/B can generate new DNA methylation sites irrespective of the pattern of methylation of template DNA.
6 DNMT1 is implicated in the maintenance of methylation patterns during cell division and methylates hemimethylated DNA. Therefore, DNMT1 copies the pattern of methylation from the parental strand to the nascent strand. 7 In cancer cells, abnormal DNA methylation of the genome is observed with both hypomethylation and hypermethylation of critical genes 8 as well as global reduction in the level of DNA methylation across the genome 9 and hypermethylation of CpG islands in the promoter regions of some specic genes such as tumor suppressor genes. This process leads to silencing of those genes due to poor recognition by transcription factors and recruitment of proteins involved in the chromatin remodeling such as the methyl-binding proteins (MBD) . 10 Contrary to sequence aberrations, DNA methylation is a reversible process.
11 More importantly, DNA methyltransferases are aberrantly deregulated and were proposed two decades ago as novel anticancer targets. 12 In fact, experiments suggest that inhibition of DNMTs can lead to demethylation and reactivation of epigenetically silenced tumor suppressor genes. 13 Moreover the emergence of the eld of "behavioral epigenetics" points to the possibility that DNA methylation inhibitors might be of value in treating mental health diseases and psychopathology disorders.
14 Since neurons are postmitotic, DNA methylation inhibitors that are not incorporated into DNA will be needed. Consequently, DNMT1 and DNMT3 15 constitute highly valuable targets for drug development.
16,17
The discovery of potent and selective inhibitors of DNMTs is of utmost importance for the development of novel therapies for the treatment of cancer 18 and for the generation of toolcompounds for studying the involvement of DNMTs in the development of various diseases. 19 Two inhibitors of DNMTs have been approved by the FDA for the treatment of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): 5-azacytidine (Vidaza) and 5-aza-2 0 -deoxycytidine (Dacogen).
20
Aer being phosphorylated, these suicide substrates are incorporated into the DNA where they trap the DNMT by forming a covalent adduct thus preventing the regeneration of the catalytic cysteine. 21 This process leads to the inactivation of the DNMT, which allows the demethylation of tumor suppressor genes and their reactivation. However, these drugs are poorly bioavailable, non-selective and are incorporated everywhere in the genome. As a consequence, there is an urgent need for new potent and selective inhibitors of DNMTs that possess good pharmacokinetic proles and that show minimal toxicity.
DNMT inhibitors that do not rely on incorporation into DNA might offer a larger therapeutic window and a viable alternative to current treatments. A number of non-nucleoside inhibitors of DNMTs have been reported in the literature.
22 Natural products such as EGCG, 23 curcumin, 24 caffeic acid, 25 parthenolide, nanaomycin A, mahanine, and genistein, 26 and drugs that are approved for other indications such as hydralazine, 27 procaine, 28 and procainamide 29 have also been shown to inhibit DNMTs.
30
The discovery of small-molecule non-nucleoside inhibitors of DNMTs has been accomplished using virtual 31 or medium throughput screening 32 on various compound collections. This process has led to the identication of a limited number of compounds that inhibit DNMTs in the micromolar or submicromolar range, such as the NSC series (Fig. 1) . Two other potent inhibitors of DNMTs, RG108 33 and SGI1027, 34 are commonly used as reference compounds in screening assays.
In 2010, Medina-Franco and Lyko reported the discovery of NSC 319745, a selective DNMT1 inhibitor (Fig. 1) . 35 This compound was identied following a virtual screening campaign of a 65 000 compound collection from the NCI database using a homology model of the catalytic domain of human DNMT1. Using a biochemical assay, a residual enzymatic activity of 66% and 128% was measured against DNMT1 and DNMT3B, respectively, in the presence of 100 mM of NSC 319745. Because of its inhibitory activity against DNMT1 and its structural features, NSC 319745 represents an attractive starting point for hit-to-lead programs. To the best of our knowledge, structure-activity-relationship (SAR) studies on this compound have never been reported.
We report herein the synthesis of NSC 319745 and the preparation of 29 analogues of this molecule. The inhibitory activity of these compounds against human DNMT1 and DNMT3A was measured and for the most potent compounds, the apparent EC 50 was calculated. The compounds were also tested against the histone methyltransferases EZH2 and DOT1L to evaluate their selectivity against other SAM-dependent enzymes. The effect of the most potent inhibitors on the methylation level in MDA-MB-231 cells was explored and molecular docking studies have been performed to propose a mode of binding for this series.
Results and discussion

Chemistry
To initiate our medicinal chemistry efforts, we began by resynthesizing NSC 319745. This compound was easily prepared from bromophenethylamine 11 using the synthetic sequence illustrated in Scheme 1. Protection of the amine 11 followed by Heck reaction with methyl acrylate and hydrogenation of the alkene furnished phenylpropionate 12. Removal of the BOC protecting group followed by amide formation using benzoyl chloride 14 and ester saponication gave NSC 319745 (10).
We then utilized this synthetic route to introduce different le-hand side aryl groups on the molecule (Scheme 2, compounds 20 to 27), to shorten the le-hand side alkyl chain (compounds 28 and 29) and to install a methyl group at the b The unsaturated analogue of NSC 319745 (compound 32) was then prepared by simply omitting the hydrogenation step from the general synthetic sequence (Scheme 3).
To study the importance of the amide N-H, we next prepared the N-methyl amide 33 by performing a chemo-selective methylation reaction on 13 followed by saponication of the ester (Scheme 4).
To evaluate potential acid surrogates, compounds 34 to 37 were prepared by amidation reaction of 10 using TBTU as the coupling agent (Scheme 5).
Introduction of modications on the right-hand side propionic acid chain was performed by reacting benzoyl chloride 14 with different amines (Scheme 6).
Using this approach, the chain was moved to the meta position (compound 38), shortened by one and two methylene units (compounds 40 and 43), or completely removed (compound 42). Compounds where the acid is reduced to the alcohol (compound 39) or deleted (compound 41) were also prepared.
We next proceeded with the introduction of an oxygen atom in the propionic acid chain by coupling 4-hydroxyphenethylamine 48 with benzoyl chloride 14 (Scheme 7). Compound 49 was then subjected to an alkylation reaction with methyl bromoacetate to provide the corresponding ester which was saponied to afford the acid 50.
A simple variation of the previous synthetic sequence allowed the introduction of a carboxylic acid group to the central linker (compound 54, Scheme 8).
We next focused our attention on the benzamide moiety of NSC 319745 and prepared the reverse amide 58 (Scheme 9). This compound was accessed starting from acid 55 by formation of a benzyl ester followed by a Heck reaction with methyl acrylate to give the cinnamate 56. Saturation of the double bond and deprotection of the benzyl ester were performed simultaneously under hydrogenation conditions to give the intermediate 57, which was then coupled with aniline 59 to provide the nal compound 58. Finally, the analogue of NSC 319745 having a reduced amide was prepared (compound 60, Scheme 10) via a reductive amination reaction between amine 19a and 5-chloro-2-methoxybenzaldehyde 61.
DNMT1 and DNMT3A inhibitory activity
Since NSC 319745 was reported to inhibit DNMT1, we started by evaluating the inhibitory activity of the resynthesized NSC 319745 (compound 10) and its 29 analogues against full-length DNMT1 using a 3 H-methyl group incorporation assay (Fig. 2) .
The results show that all the compounds give less than 20% inhibition against DNMT1 compared to 100% inhibition by reference compound SGI1027. The compounds that gave the highest inhibition are the 4-nitrobenzamide 24 (14%), the phenol 49 (16%), and the acid 50 (15%). Contrary to previous reports, the resynthesized NSC 319745 (compound 10) showed no signicant inhibitory activity against DNMT1 (ca. 2.9%). To conrm this result, we retested compound 10 at 50 mM, 100 mM, and 200 mM and observed no detectable inhibition of DNMT1 activity. These results indicate that NSC 319745 is not an inhibitor of DNMT1 in our enzymatic test.
The activity of the compounds was then measured against DNMT3A at 10 mM and 100 mM using a nonradioactive assay based on uorescence detection using the human catalytic DNMT3A (Fig. 3) . 36 Interestingly, compounds 24, 26, 28, 29, 49, 50, and 54 showed greater than 60% inhibition at 100 mM. All of these compounds, except 26, also showed more than 13% inhibition at 10 mM. Resynthesized NSC 319745 (10) showed negligible inhibitory activity against DNMT3A at both concentrations, in agreement with previous literature reports indicating that NSC 319745 does not inhibit DNMT3B.
A complete inhibition curve was measured for the compounds that showed greater than 60% inhibitory activity against DNMT3A at 100 mM. An apparent EC 50 of 36 mM was calculated for compound 49 (Fig. 4) . Complete inhibition could not be reached for the other compounds at concentrations up to 100 mM, thus making the determination of EC 50 not possible. In order to verify the selectivity of the prepared compounds against other SAM-dependent methyltransferases, we tested them against EZH2 and DOT1L. EZH2 (Enhancer of Zeste homolog 2) catalyzes the methylation on lysine 27 of histone 3 (H3K27). 37 Viré et al. have demonstrated that EZH2 serves as a recruitment platform for DNMTs, thus suggesting a connection between these two epigenetic enzymes in gene silencing. 
39
Using a 3 H-SAM assay, no inhibition of EZH2 or DOT1L could be observed at concentrations up to 80 mM, indicating the specicity of the compounds against DNA methylation.
Molecular modeling
Molecular docking of 49 was performed using the ForecasterÒ platform 40 from Molecular Forecaster to establish its binding mode using the crystal structure of the human catalytic Dnmt3A/3L complex (PDB: 2QRV). The results from the docking show a linear conformation for inhibitor 49 (green in Fig. 5 ) with the amide group being in the expected trans conformation.
The ortho methoxy group is found to be oriented in the same direction as the amide carbonyl group oxygen. When the binding of 49 is compared with that of SAH (magenta in Fig. 5) , we observe an overlap of the phenol moiety of 49 with the SAH adenine group. The exible chain of the inhibitor extends inside the binding pocket in the same orientation as the homocysteine chain of SAH. These similarities in binding mode seem to suggest that inhibitor 49 binds in the SAM/SAH binding site.
Cellular activity
The impact of the most potent DNMT3A inhibitors on the methylation level was evaluated in MDA-MB-231 breast cancer cells using a luminometric methylation assay. The global methylation level was determined in the presence of 100 mM and 200 mM inhibitors using a methylation sensitive restriction assay (HpaII/Msp1) followed by luminometric (LUMA) determination of cleavage by HpaII (sensitive to methylation at CC m GG) versus Msp1 (insensitive to CC m GG methylation). Compounds that were not sufficiently soluble in aqueous media (compounds 28 and 29) or that were cytotoxic (compounds 24, 26 and 49) were not tested. Compounds 50 and 54 were thus selected for cell studies based on potency, solubility and absence of cytotoxicity (Fig. 6 ).
To our great disappointment, compound 50 induced no signicant reduction of the methylation level at 100 mM and 200 mM. Similarly, when the cells were incubated in the presence of compound 54, no effect on the methylation level could be detected at 100 mM while only a minor reduction was observed at 200 mM. Although compounds 50 and 54 were effective in inhibiting DNA methyltransferase activity in vitro, they did not show signicant activity in cells as far as global DNA measurements are concerned in contrast to the classical DNA methylation inhibitor 5-azaC which dramatically reduced DNA methylation in the same experiment. There could be several explanations for the discrepancy between in vitro and in vivo potencies of these agents. First, there might be permeability issues that reduce the availability of the drug in the cell or in the nucleus. The second possibility is that in contrast to 5-azaC which is incorporated into DNA and trap the DNMTs, the compounds tested are catalytic inhibitors of DNMTs and it is possible that the level of inhibition is insufficient to block DNA methylation during replication. We have previously shown that inhibition of DNMT results in inhibition of DNA replication which in turn reduces the level of substrate for DNA methylation and thus the impact of DNMT inhibition on methylation of newly synthesized DNA. 41 Further modications of the compounds are possibly required to increase potency and permeability in order to achieve effective inhibition of DNA methylation during DNA synthesis in living cells.
Conclusion
The identication of small-molecules that modulate epigenetic processes can open new avenues for the treatment of cancer, 42 mental health diseases, and psychopathology disorders.
43 Drugs that target DNMTs could also increase the options for treatment in the context of combination therapy. 44 We performed the resynthesis of NSC 319745 (a compound discovered by virtual screening against DNMT1) and 29 analogues and demonstrated that, contrary to previous reports, NSC 319745 is not a DNMT inhibitor. All the analogues of NSC 319745 showed less than 20% inhibition against DNMT1 at 100 mM. Seven compounds were found to signicantly inhibit DNMT3A (compounds 24, 26, 28, 29, 49, 50, and 54). An inhibition curve against DNMT3A was measured for compound 49, giving an apparent EC 50 of 36 mM. Molecular docking studies suggest that compound 49 binds in the SAM pocket. For all the compounds prepared, no activity was detected against EZH2 and DOT1L, two lysine histone methyltransferases. A moderate reduction of the methylation level in MDA-MB-231 cells was observed for compound 54 at 200 mM. Compounds 49 and 54 are two small-molecule inhibitors of DNMT3 that could represent a potential new starting point for lead optimization programs. Medicinal chemistry activities on this series to generate permeable and more potent compounds are underway in our laboratories and results will be reported in due course.
Experimental section
Chemistry
General methods. All reactions were run under an argon atmosphere in non ame dried glassware. Unless otherwise stated, commercial reagents were used without further puri-cation. Nuclear magnetic resonance spectra were recorded on a Bruker Avance-III 300 MHz spectrometer. Chemical shis for 1 H-NMR spectra are recorded in parts per million from tetramethylsilane with the solvent resonance as the internal standard. Data are reported as follows: chemical shi, multiplicity
, coupling constant J in Hz, integration, and assignment. Chemical shis for 13 C spectra are recorded in parts per million from tetramethylsilane using the central peak of deuterochloroform (77.00 ppm) as the internal standard. All 13 C-NMR spectra were obtained with complete proton decoupling. Purity of tested compounds was determined by HPLC analysis on a Beckman Gold HPLC system using a C18 column and acetonitrile (containing 0.01% of TFA) and water (containing 0.01% of TFA) as the mobile phase. The purity of all nal compounds is greater than 95%. Compounds 41, 42, 43, 49, and 50 were synthesized following a literature procedure.
45
N-BOC protection: general procedure. In a round bottom ask, 10 mmol of amine 11 or 15b and c (1.0 eq.), 10 mmol of BOC 2 O (1.0 eq.) and 20 mmol of Et 3 N (2.0 eq.) in 50 mL of i-PrOH were stirred at r.t. Progress of the reaction was monitored by TLC (hexane-EtOAc, 4 : 1). Aer reaction completion, the solvent was evaporated under vacuum. The residue was puried by ash column chromatography (hexane-EtOAc, 10 : 1) to afford the N-BOC amines 16a-c.
Heck reaction: general procedure. A mixture of 16a-c (1.0 mmol, 1.0 eq.), LiCl (2.0 mmol, 2.0 eq.) and PdCl 2 (PPh 3 ) 2 (0.05 mmol, 0.05 eq.) in DMF (4 mL) in a microwave vial (5 mL) was degassed by bubbling argon through the solution for 10 min. Et 3 N (2 mmol, 2.0 eq.) and methyl acrylate 17a-c (1.25 mmol, 1.25 eq.) were added, and the mixture was degassed again for 5 min. Then, the sealed vial was stirred in a microwave at 130
C for 3 h. The reaction mixture was diluted with EtOAc and washed with aq. sat. solution of NaHCO 3 . The organic layer was separated, dried over anhydrous Na 2 SO 4 , ltered and concentrated under vacuum. The crude mixture was puried by ash column chromatography (hexane-EtOAc, 8 : 1) to afford compounds 18a-e. Hydrogenation: general procedure. A solution of the substrate 18a-e in MeOH (0.06 M) was stirred at room temperature over a 10% Pd/C catalyst (10% w/w) under a hydrogen atmosphere for 3 h. Aer reaction completion, the mixture was ltered through a pad of celite and washed with CH 2 Cl 2 . The collected organic phase was evaporated under vacuum. The crude product was used directly in the next step without further purication.
N-BOC deprotection: general procedure. CF 3 CO 2 H (50 eq.) was added dropwise to a 0 C 0.25 M anhydrous CH 2 Cl 2 solution of the N-BOC protected compound (1.0 eq.) obtained from the previous step. The resulting mixture was stirred for 3 h at r.t. and the solvent was removed under reduced pressure. The residue was taken up in CH 2 Cl 2 and washed twice with aq. sat. solution of NaHCO 3 . The organic layer was separated, dried over anhydrous Na 2 SO 4 , ltered and concentrated under vacuum. The product 19a-e was obtained as a free base and was used directly in the next step without further purication. Amide synthesis: general procedure. A 0.4 M anhydrous CH 2 Cl 2 solution of the benzoyl chloride (1.1 eq.) was added dropwise to a 0 C anhydrous 0.2 M CH 2 Cl 2 solution of amine 19a-e (1.0 eq.) and Et 3 N (2.0 eq.). The resulting mixture was stirred at r.t. Aer completion of the reaction, as indicated by TLC analysis, the mixture was diluted with CH 2 Cl 2 and washed with brine. The organic layer was separated, dried over anhydrous Na 2 SO 4 , ltered and concentrated under vacuum. The residue was puried by ash column chromatography (1% MeOH/CH 2 Cl 2 ), providing the corresponding amide. In the FlashplateÔ assay, the reaction was performed in a 10 mL total reaction volume in low volume NBSÔ 384-well microplates (Corning), containing the tested compound (up to 1% DMSO), 1 mM of a SAM/[methyl- 46 was added in each well (100 nM) and mixed with the chemical compounds at desired concentrations and freshly prepared SAM (20 mM nal concentration) to start the reaction in a total volume of 50 mL. Aer 1 hour incubation at 37 C each well was washed three times with PBS, Tween-20 0.05%, NaCl (500 mM) and three more times with PBST. Specic uorescent signals were detected with the methylation-sensitive restriction enzyme Hpy-CH4IV (NEB) as described and measured on a Perkin Elmer Envision detector. EZH2 inhibition assay. PRC2, biotinylated nucleosome (both prepared in-house), H3K27Me3 activator peptide (RKQLAT-KAARK(Me3)SAPATGGVKKP-NH 2 , New England Peptide, Gardner, MA) and compound (in DMSO) were incubated in 50 mM Tris, pH 8.5, 5 mM MgCl 2 , 1 mM DTT, 70 mM Brij-35, and 0.1 mg mL À1 BSA for 30 minutes. Reaction was initiated by addition of 3 H-SAM to nal conditions of 5 nM PRC2, 200 nM nucleosome (concentration expressed as H3), activator peptide (3.6 mM) and 200 nM 3 H-SAM in a total volume of 25 mL in 384 well Greiner plates. For compound analysis, assays were ten point doseresponses with a nal total DMSO of 0.8% (v/v). Typically assays were run for 60 minutes with <35% substrate turnover. Aer that, reaction assays were quenched by addition of 20 mL of 2 mM SAH and 200 mM EDTA in 50 mM Tris, pH 8.5. Reactions were transferred to streptavidin coated FlashPlates, incubated for 2 hours, aspirated, washed, and read on a TopCount. DOT1L inhibition assay. Run in a manner similar to the EZH2 assay except that GST-DOT1L 1-416 (prepared in-house 47 ) was used at a nal concentration of 12 nM enzyme, 30 nM biotinylated oligonucleosome, 500 nM 3H-SAM and 30 minute reaction time course in a buffer consisting of 50 mM Tris, pH 8.5, 5 mM MgCl 2 , 1 mM DTT, and 80 mM Tween-20. Subsequent quench and work-up were as for EZH2.
Cell line and culture conditions. Breast MDA-MB-231 cells (#HTB-231) were purchased from the American Type Culture Collection (ATCC, Manassas, Virginia). MDA-MB-231 cells were cultured in Dulbecco's modied Eagle's medium (Invitrogen). 2 Â 10 6 MDA-MB-231 cells were plated the day before treatment on 10 cell culture plates. The following day, the cells were treated with compounds at concentrations of 100 and 200 mM and with 1 mM of 5-Azadc. The treatment was repeated for six days, every second day. On day six, cells were harvested.
DNA extraction and luminometric methylation assay. DNA was extracted by phenol-chloroform as follows: cells were resuspended and incubated in DNA extraction buffer (500 mL) containing proteinase K (20 mL; 20 mg ml À1 ; Roche, Basel, 48 Peak heights for C and A represent the HpaII and MspI cuts (methylation) and EcoRI (input DNA), respectively. The formula for calculating % genomic methylation is: 1-[(HpaII (C)/EcoRI (A)/MspI (C)/EcoRI (A))] Â 100. All samples were run in triplicate.
